These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33203938)

  • 1. Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation.
    Tecchio C; Cassatella MA
    Cell Mol Immunol; 2021 Apr; 18(4):905-918. PubMed ID: 33203938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
    Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.
    Luznik L; Fuchs EJ
    Immunol Res; 2010 Jul; 47(1-3):65-77. PubMed ID: 20066512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
    Zaghi E; Calvi M; Di Vito C; Mavilio D
    Front Immunol; 2019; 10():2794. PubMed ID: 31849972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
    Gu G; Yang JZ; Zhang JQ; Sun LX
    Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paired Donor and Recipient Immunophenotyping in Allogeneic Hematopoietic Stem Cell Transplantation: A Cellular Network Approach.
    Wittenbecher F; Lesch S; Kolling S; Blau IW; Vuong L; Borchert F; Movasshagi K; Tietze-Bürger C; Penack O; Ahn J; Bullinger L; Frentsch M; Na IK
    Front Immunol; 2022; 13():874499. PubMed ID: 35677053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation.
    Ciftciler R; Goker H; Buyukasık Y; Karaagac T; Aksu S; Tekin F; Demiroglu H
    Transfus Apher Sci; 2020 Feb; 59(1):102597. PubMed ID: 31311753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Barzin A; Geurten C; Willems E; Baron F; Beguin Y; Servais S
    Rev Med Liege; 2022 May; 77(5-6):345-353. PubMed ID: 35657193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
    Klyuchnikov E; El-Cheikh J; Sputtek A; Lioznov M; Calmels B; Furst S; Chabannon C; Crocchiolo R; Lemarié C; Faucher C; Bacher U; Alchalby H; Stübig T; Wolschke C; Ayuk F; Reckhaus ML; Blaise D; Kröger N
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):382-6. PubMed ID: 24321747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CD34
    Pedraza A; Salas MQ; Rodríguez-Lobato LG; Charry P; Suárez-Lledo M; Martínez-Cibrian N; Doménech A; Solano MT; Arcarons J; de Llobet N; Rosiñol L; Gutiérrez-García G; Avilés FF; Urbano-Ispízua Á; Rovira M; Martínez C
    Transplant Cell Ther; 2023 Mar; 29(3):181.e1-181.e10. PubMed ID: 36526259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reconstitution kinetics of dendritic cells following allogeneic hematopoietic stem cell transplantation].
    Fu HX; Zhang XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):222-6. PubMed ID: 18315936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
    Taimur S; Askar M; Sobecks R; Rybicki L; Warshawsky I; Mossad S
    Transpl Infect Dis; 2014 Feb; 16(1):61-6. PubMed ID: 24251680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.